This paper explores how the grand strategies of a Slovenian firm, LEK, evolved during the period 1992-2002. Using a unique methodological framework, data was collected qualitatively from published sources in order to identify and explore the strategic actions that LEK realized. The findings showed that LEK realized organic growth and external finance-raising strategies together with a number of incremental strategic actions such as those relating to mergers and acquisitions and organic concentric diversification.
By focusing upon how the strategies and strategic actions realized by LEK evolved over an 11-year period, this paper has contributed to a gap in the existing literature about strategy development by pharmaceutical firms based in transitional economies